180059-04-5

Basic information

• Product Name: 1H-Pyrrole-2,4-dicarboxylicacid,3-amino-,dimethylester(9CI)
• Synonyms: 1H-Pyrrole-2,4-dicarboxylicacid,3-amino-,dimethylester(9CI);2,4-Dimethyl 3-amino-1H-pyrrole-2,4-dicarboxylate;Dimethyl 3-Aminopyrrole-2,4-dicarboxylate
• CAS NO: 180059-04-5
• Molecular Formula: C₈H₁₀N₂O₄
• Molecular Weight: 198.18
• Product Categories: AMINOACID
• Mol File: 180059-04-5.mol

Chemical Properties

• Melting Point: 165-166 °C
• Boiling Point: 395.696°C at 760 mmHg
• Flash Point: 193.11°C
• Appearance: /
• Density: 1.359g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.579
• PKA: 14.26±0.50(Predicted)
• CAS DataBase Reference: 1H-Pyrrole-2,4-dicarboxylicacid,3-amino-,dimethylester(9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: 1H-Pyrrole-2,4-dicarboxylicacid,3-amino-,dimethylester(9CI)(180059-04-5)
• EPA Substance Registry System: 1H-Pyrrole-2,4-dicarboxylicacid,3-amino-,dimethylester(9CI)(180059-04-5)

Safety Data

• Hazardous Substances Data: 180059-04-5(Hazardous Substances Data)

Usage

Uses

Used in Chemical Synthesis:
1H-Pyrrole-2,4-dicarboxylic acid, 3-amino-, dimethyl ester (9CI) is used as a building block in the synthesis of various organic compounds. Its unique structure allows for the creation of a wide range of chemical entities, making it a valuable component in the development of new materials and molecules.
Used in Pharmaceutical Development:
In the pharmaceutical industry, 1H-Pyrrole-2,4-dicarboxylic acid, 3-amino-, dimethyl ester (9CI) serves as a precursor in the production of drugs. Its presence in the molecular structure can contribute to the therapeutic properties of medications, potentially leading to the discovery of new treatments for various diseases and conditions.
Used in Drug Discovery:
1H-Pyrrole-2,4-dicarboxylicacid,3-amino-,dimethylester(9CI)'s potential biological activity positions 1H-Pyrrole-2,4-dicarboxylic acid, 3-amino-, dimethyl ester (9CI) as a candidate for drug discovery. Researchers can explore its interactions with biological targets to identify possible applications in therapeutic interventions, further expanding its utility in the healthcare sector.

InChI:InChI=1/C8H10N2O4/c1-13-7(11)4-3-10-6(5(4)9)8(12)14-2/h3,10H,9H2,1-2H3

Upstream product

• 13433-00-6 diethyl aminomalonate hydrochloride 
• 124-41-4 sodium methylate 
• 94-05-3 ethyl (ethoxymethylene)cyanoacetate 
• 6829-40-9 aminomalonic acid diethyl ester 
• 42466-67-1 ethyl (ethoxymethylene)cyanoacetate 
• 67-56-1 methanol 

Downstream Products

• 364046-18-4 1S-5-O-tert-butyldimethylsilyl-1,4-dideoxy-1-C-[(4-methyoxypyrrolo[3,2-d]pyrimidin-9-N-(benzyloxomethyl)-7-yl)]-1,4-imino-2,3-O-isopropylidine-D-ribitol 
• 299916-62-4 7-N-benzyloxymethyl-9-bromo-9-deaza-6-O-methylhypoxanthine 
• 5655-01-6 9-deazahypoxanthine 
• 1026012-16-7 5-(benzyloxymethyl)-4-methoxy-5H-pyrrolo[3,2-d]pyrimidine 
• 364046-19-5 1S-N-tert-butoxycarbonyl-5-O-tert-butyldimethylsilyl-1,4-dideoxy-1-C-[(4-methyoxypyrrolo[3,2-d]pyrimidin-9-N-(benzyloxomethyl)-7-yl)]-1,4-imino-2,3-O-isopropylidine-D-ribitol 
• 402477-37-6 (2S,3S,4R,5R)-tert-butyl 2-(5-(benzyloxymethyl)-4-methoxy-5H-pyrrolo[3,2-d]pyrimidin-7-yl)-3,4-dihydroxy-5-(hydroxymethyl)pyrrolidine-1-carboxylate 
• 917595-31-4 (6aR,8S,9S,9aR)-tert-butyl 8-(5-(benzyloxymethyl)-4-methoxy-5H-pyrrolo[3,2-d]pyrimidin-7-yl)-9-hydroxy-2,2,4,4-tetraisopropyltetrahydro-[1,3,5,2,4]trioxadisilocino[7,6-b]pyrrole-7(8H)-carboxylate 
• 1163713-16-3 (6aR,8S,9R,9aR)-tert-butyl 8-(5-(benzyloxymethyl)-4-methoxy-5H-pyrrolo[3,2-d]pyrimidin-7-yl)-9-hydroxy-2,2,4,4-tetraisopropyltetrahydro[1,3,5,2,4]trioxadisilocino[7,6-d]pyrrole-7(8H)-carboxylate 
• 402477-42-3 (2S,3S,4R,5R)-tert-butyl 2-(5-((benzyloxy)methyl)-4-methoxy-5H-pyrrolo[3,2-d]pyrimidin-7-yl)-3,4-dihydroxy-5-((trityloxy)methyl)pyrrolidine-1-carboxylate 
• 577978-31-5 (2S,3S,4R,5R)-tert-butyl 2-(5-((benzyloxy)methyl)-4-methoxy-5H-pyrrolo[3,2-d]pyrimidin-7-yl)-3-hydroxy-4-((4-methoxybenzyl)oxy)-5-((trityloxy)methyl)pyrrolidine-1-carboxylate 
• 402477-45-6 (2S,3S,4R,5R)-tert-butyl 2-(5-((benzyloxy)methyl)-4-methoxy-5H-pyrrolo[3,2-d]pyrimidin-7-yl)-4-hydroxy-3-((4-methoxybenzyl)oxy)-5-((trityloxy)methyl)pyrrolidine-1-carboxylate 
• 1163713-17-4 (2S,3S,4S,5R)-tert-butyl 2-(5-((benzyloxy)methyl)-4-methoxy-5H-pyrrolo[3,2-d]pyrimidin-7-yl)-4-hydroxy-3-((4-methoxybenzyl)oxy)-5-((trityloxy)methyl)pyrrolidine-1-carboxylate 
• 779326-74-8 4-oxo-4,5-dihydro-3H-pyrrolo[3,2-d]pyrimidine-7-carboxylic acid methyl ester 
• 65996-58-9 9-deazaguanine 

Relevant articles and documents

A short, facile synthesis of 2-amino-1,5-dihydro-4H-pyrrolo[3,2-d]- pyrimidin-4-one (9-deazaguanine)

9-Deazaguanine has been synthesized in four steps in an overall isolated yield of 18% from ethyl (ethoxymethylene)cyanoacetate and diethyl aminomalonate.

ANTIVIRAL AZASUGAR-CONTAINING NUCLEOSIDES

Disclosed are compounds comprising an azasugar attached to a heterocyclic base, including pharmaceutically acceptable salts thereof, suitable for use in inhibiting viral RNA polymerase activity or viral replication, and treating viral infections. The compounds are characterized, in part, by favorable pharmacokinetics for the active pharmaceutical ingredient, particularly in conjunction with enteral administration, including, in particular, oral administration. Also disclosed are pharmaceutical compositions comprising one or more compounds mentioned above, or pharmaceutically acceptable salts thereof, as well as methods for preparing same. Also provided are methods for inhibiting viral RNA polymerase activity, viral replication, and treating viral infections.

COMPOSITIONS AND METHODS FOR INHIBITING VIRAL POLYMERASE

Provided are compounds of Formula (I) as described herein. Compounds of Formula (I) are useful in methods of inhibiting viral RNA polymerase activity and viral replication. Also provided are pharmaceutical compositions comprising compounds of Formula (I), as well as methods of treating viral infections using compounds of Formula (I).

Development of a practical synthesis of a purine nucleoside phosphorylase inhibitor: BCX-4208

A practical synthesis of the purine nucleoside phosphorylase (PNP) inhibitor BCX-4208 (1) was accomplished in three telescoped steps. Mannich condensation of the 4-benzyloxy-9-deazahypoxanthine with (3R,4R)-3-hydroxy-4- (hydroxymethyl)pyrrolidine and formaldehyde followed by removal of the protecting group and crystallization furnished the desired product as a hydrochloride salt in 85% overall yield and 99.8% purity. A scalable synthesis of 9-deazahypoxanthine is also reported. 2009 American Chemical Society.

Carboxy pyrrole, process of preparing and use as precursor

4-Oxo-4,5-dihydro-3H-pyrrolo[3,2-d] pyrimidine-7-carboxylic acid methyl ester and process for preparing are provided. The 4-oxo-4,5-dihydro-3H-pyrrole[3,2-d] pyrimidine-7-carboxylic acid methyl ester is useful as a precursor for providing 9-deaza-hypoxanthine, a key intermediate for producing certain PNP inhibitors.